Siren, L.L.C portfolio
Type not verifiedPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 13, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Siren, L.L.C reported a $4.9 bn portfolio of 115 positions to the SEC as of the end of Q2 2026. Its largest positions are SRRK, KYMR, ERAS. During the quarter it opened Abivax and Relay Therapeutics.
Sections with a free account
What changed this quarter
78 positions with a change (17 new, 32 added to, 21 trimmed, 8 sold); also, 4 entered through an IPO, 1 exited through an acquisition or merger, 3 entered through a spin-off. 9 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedParabilis MedicinesPBLS1.7% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Abivax+1.6 ppof portfolioNew— → 1.6%
- Scholar Rock Holding−12%fewer sharesReduced14.8% → 10.7%
- Relay Therapeutics+1.4 ppof portfolioNew— → 1.4%
- Enliven Therapeutics+138%more sharesIncreased0.8% → 1.8%
- Edgewise Therapeutics−28%fewer sharesReduced3.9% → 2.6%
- Rhythm Pharmaceuticals+57%more sharesIncreased1.7% → 2.6%
- Revolution Medicines−19%fewer sharesReduced3.0% → 3.4%
- Capital One Financial+0.7 ppof portfolioNew— → 0.7%
- Kymera Therapeutics−7.9%fewer sharesReduced7.4% → 6.8%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Scholar Rock HoldingSRRK10.7%
- Kymera TherapeuticsKYMR6.8%
- ErascaERAS4.2%
- VeradermicsMANE4.1%
- Tango TherapeuticsTNGX3.9%
- Revolution MedicinesRVMD3.4%
- Bicara TherapeuticsBCAX3.4%
- Arrowhead PharmaceuticalsARWR2.8%
- Beone MedicinesONC2.7%
- Edgewise TherapeuticsEWTX2.6%
- Rhythm PharmaceuticalsRYTM2.6%
- Lexicon PharmaceuticalsLXRX2.2%
- Enliven TherapeuticsELVN1.8%
- Spyre TherapeuticsSYRE1.7%
- Parabilis MedicinesPBLS1.7%
Portfolio by sector
- ● Health Care 93%
- ● Information Technology 4%
- ● Financials 1%
- ● Communication Services 1%
- ● Consumer Discretionary 1%
13F filings with amendments or confidential positions
- 13F Q1 2025 ↗filed May 14, 2025Amendment of May 23, 2025 (replaces the original) ↗
Declared options (2)
Besides stocks, Siren, L.L.C declared 2 calls (they gain if it rises) with a notional of $15.6M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified: we have not assigned a type because we found no document that is enough to tell. Most 13F filers are in this situation: we only review in depth those that meet the portfolio criteria.
Not counted as a concentrated manager: its portfolio is not within 5 to 100 positions; its top 10 positions are under 45%. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Glenview Capital ManagementInvestment firm · $5.0 bn
- MFN Partners ManagementInvestment firm · $4.8 bn
- Sachem Head Capital ManagementInvestment firm · $4.8 bn
- Kayne Anderson Capital Advisors$5.1 bn
- Maple Rock Capital PartnersInvestment firm · $5.1 bn
- Stockbridge PartnersInvestment firm · $4.8 bn